CAPITOL COUNSEL LLC for GENENTECH
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| ROBERT DIAMOND | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Health Issues HCR
340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy, including related provisions in S. 652, the Safe Step Act. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research and novel product development.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| ROBERT DIAMOND | — |
| JOSEPH EANNELLO | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.